ongoing

The objective of the SCHOLAR-2 study is to evaluate whether is it safe and effective to continue trastuzumab in patients with early stage HER2 positive breast cancer who develop mild, minimally symptomatic or asymptomatic systolic left ventricular dysfunction.

Primary outcome:

The primary efficacy outcome will be the likelihood of completing trastuzumab as planned at its initiation.

The primary safety outcome will be left ventricular ejection fraction.

Study Type

Interventional - Drug

NO. of Countries

TBD

NO. of Sites

TBD

NO. of Participants

120

Study Period

2020-2023

Sponsor

PHRI

Juravinski Hospital and Cancer Centre Foundation

Hadley H. Chamberlain Memorial Award

Canadian Cancer Society

Back To Top